Albireo Pharma, Inc. (ALBO): Price and Financial Metrics
Albireo Pharma, Inc. (ALBO)
Today's Latest Price: $24.45 USD
0.29 (-1.17%)
Updated Feb 18 8:00pm
Add ALBO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ALBO Stock Summary
- For ALBO, its debt to operating expenses ratio is greater than that reported by only 0.37% of US equities we're observing.
- ALBO's price/sales ratio is 86.15; that's higher than the P/S ratio of 97.47% of US stocks.
- As for revenue growth, note that ALBO's revenue has grown -68.97% over the past 12 months; that beats the revenue growth of only 1.99% of US companies in our set.
- Stocks that are quantitatively similar to ALBO, based on their financial statements, market capitalization, and price volatility, are XPL, HTBX, KPTI, CLSN, and PZG.
- Visit ALBO's SEC page to see the company's official filings. To visit the company's web site, go to www.albireopharma.com.
ALBO Daily Price Range
ALBO 52-Week Price Range
ALBO Stock Price Chart More Charts
ALBO Price/Volume Stats
| Current price | $24.45 | 52-week high | $38.69 |
| Prev. close | $24.74 | 52-week low | $16.13 |
| Day low | $23.90 | Volume | 81,200 |
| Day high | $24.99 | Avg. volume | 121,756 |
| 50-day MA | $23.97 | Dividend yield | N/A |
| 200-day MA | $25.31 | Market Cap | 310.20M |
Albireo Pharma, Inc. (ALBO) Company Bio
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders. The company is based in Boston, Massachusetts.
Top Stories View All
Best & Worst Performing Stock Industries for February 18, 2020
Best & Worst Performing Small Cap Stocks for February 18, 2020
Best & Worst Performing Mid Cap Stocks for February 18, 2020
Best & Worst Performing Large Cap Stocks for February 18, 2020
Best & Worst Performing Mega Cap Stocks for February 18, 2020
View All Top Stories
Loading social stream, please wait...